Compositions for inhibiting checkpoint gene expression and uses thereof
AssigneeIdera Pharmaceuticals, Inc.
InventorsSudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.
Claims17
A 3rd generation antisense (3GA) compound comprising two oligonucleotides linked at their 5′ ends, each oligonucleotide, independently, consists of 12 to 30 nucleotides having a nucleobase sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of SEQ ID NO:
- 387, SEQ ID NO:
- 388, SEQ ID NO:
- 389, SEQ ID NO:
- 390, SEQ ID NO:
- 391, SEQ ID NO:
- 392, SEQ ID NO:
- 393, SEQ ID NO:
- 394, SEQ ID NO:
- 395, SEQ ID NO:
- 396, SEQ ID NO:
- 397, SEQ ID NO:
- 398, SEQ ID NO:
- 399, SEQ ID NO:
- 400, SEQ ID NO:
- 401, SEQ ID NO:
- 402, SEQ ID NO:
- 403, SEQ ID NO:
- 404, SEQ ID NO:
- 405, or SEQ ID NO:
- 406.
Dependencies are inferred from the claim text.